Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is 6.16 as of 2026-10-06T15:55:13.735Z.
Consensus retrieved: 2026-10-06T08:18:19.864Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T15:55:13.735Z.
Quote observation: 2026-10-06T15:55:05.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 23f55305a71a3950b031d13a123c7a4da2ce3ae96893c1a2d36d58e557527924
Forward PE Ratio (6.16) = Dated Quote Price ($4.55) / Consensus Forward EPS ($0.74)
FORWARD PE RATIO
6.16
SECTOR MEDIAN · HEALTHCARE
19.77
median of 173 covered companies
CURRENT VS SECTOR MEDIAN
-68.84%
vs the sector median at left
Arbutus Biopharma Corp
Market Cap
$899.78M
Forward PE Ratio
6.16
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Arbutus Biopharma Corp (ABUS) | $899.78M | 6.16 |
| Bioventus Inc. (BVS)vs › | $897.66M | 17.01 |
| Corvus Pharmaceuticals, Inc. (CRVS)vs › | $888.84M | N/A |
| HealthStream, Inc. (HSTM)vs › | $914.10M | 42.40 |
| Rigel Pharmaceuticals, Inc. (RIGL)vs › | $875.80M | 13.80 |
| CeriBell, Inc. (CBLL)vs › | $933.21M | N/A |
| Monte Rosa Therapeutics, Inc. (GLUE)vs › | $860.00M | N/A |
| Odyssey Therapeutics, Inc. (ODTX)vs › | $947.18M | N/A |
| MoonLake Immunotherapeutics (MLTX)vs › | $949.24M | N/A |
| Beta Bionics, Inc. (BBNX)vs › | $843.33M | N/A |
Trailing P/E
5.8
reported TTM EPS
Forward P/E
6.2
consensus EPS · fiscal year ending 2026-12-31
The gap between the two multiples is the consensus growth expectation: analysts' forward EPS of $0.74 implies -5.1% EPS decline vs the reported trailing $0.78.
At the dated quote price of $4.55, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $0.74 | $0.74 – $0.74 | 1 | 6.2x |
| 2027-12-31 | $-0.08 | $-0.08 – $-0.08 | 1 | n/m |
| 2028-12-31 | $-0.14 | $-0.14 – $-0.14 | 1 | n/m |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
